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Abstract Genome sequencing of Streptomyces, myxobacte-
ria, and fungi showed that although each strain contains genes
that encode the enzymes to synthesize a plethora of potential
secondary metabolites, only a fraction are expressed during
fermentation. Interest has therefore grown in the activation of
these cryptic pathways. We review current progress on this
topic, describing concepts for activating silent genes, utiliza-
tion of “natural”mutant-type RNA polymerases and rare earth
elements, and the applicability of ribosome engineering to
myxobacteria and fungi, the microbial groups known as ex-
cellent searching sources, as well as actinomycetes, for sec-
ondary metabolites.
Keywords Silent gene activation . Strain improvement .
Ribosome engineering . Rare earth elements
Introduction
Applied microbiology seeks, for example, to identify the latent
activities of microorganisms and to enhance these activities at
the industrial level by strain improvement. Current methods of
strain improvement, ranging from classical random approaches
to metabolic engineering, however, are either costly or labor-
intensive (Santos and Stephanopoulos 2008). Moreover, after
1970, the rate of discovery of useful compounds declined
progressively, despite the constant need for new and improved
drugs to combat emerging and reemerging infectious diseases
and cancer. Recent advances in DNA sequencing technologies
have enabled multiple genomes to be sequenced rapidly and
inexpensively. Streptomyces genome sequencing showed that
each strain contains genes that encode the enzymes to synthe-
size 20 or more potential secondary metabolites (Bentley et al.
2002; Ikeda et al. 2003; Ohnishi et al. 2008), only a fraction of
which are expressed during fermentation. These cryptic bio-
synthetic pathways may produce many novel bioactive com-
pounds with the potential to rejuvenate stalled drug discovery
pipelines. Methods to activate these silent biosynthetic path-
ways are thus of major interest. The key issue for the success of
this approach is to find ways to induce or enhance the expres-
sion of cryptic or poorly expressed pathways to provide mate-
rial for structure elucidation and biological testing. Thus,
strategies for rapid strain improvement will likely shift from
the improved expression of well-known, highly productive,
secondary metabolites of fermentation to the expression of
novel and often cryptic secondary metabolite pathways (Baltz
2011). This approach may solve the early stage discovery
problems of: (a) inducing some level of expression of cryptic
biosynthetic gene clusters [waking the sleeping genes] and (b)
rapidly increasing product yields to obtain enough material to
characterize chemically and biologically [early stage yield
enhancement].
The notion of “ribosome engineering” originally came from
the finding, that a Streptomyces lividans strain with an altered
ribosomal S12 protein that confers streptomycin resistance
produced abundant quantities of the blue-pigmented antibiotic
actinorhodin, although S. lividans normally does not produce
antibiotics due to the dormancy of the antibiotic biosynthesis
genes (Shima et al. 1996). On the other hand, the bacterial
alarmone ppGpp, produced on the ribosome, was found to bind
to RNA polymerase (RNAP) (Artsimovitch et al. 2004), even-
tually initiating the production of antibiotics (Bibb 2005; Ochi
2007). This suggested that RNAPmodification, by introducing
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a rifampicin resistance mutation, may mimic the ppGpp-bound
form, activating the expression of biosynthetic gene clusters
(Lai et al. 2002; Xu et al. 2002). Consequently, we have
developed a method, termed ribosome engineering, to activate
or enhance the production of secondary metabolites by target-
ing ribosomal protein S12, as well as other ribosomal proteins
and translation factors, or RNAP, hypothesizing that bacterial
gene expression may be increased dramatically by altering
transcription and translation pathways.
Ribosome engineering is characterized by its applicability
to both strain improvement and silent gene activation to
identify novel secondary metabolites. The fundamental mech-
anism by which ribosome engineering affects antibiotic pro-
duction has been summarized in earlier reviews (Ochi et al.
2004; Ochi 2007), as has the outline of this technology (Baltz
2011; Chiang et al. 2011; Olano et al. 2008; Xie et al. 2009).
Therefore, the present review highlights recent advances on
this topic.
Impact on strain improvement
Since many antibiotics, such as streptomycin, target the ribo-
some, ribosome mutants that confer antibiotic resistance may
be obtained by simply selecting mutants on drug-containing
plates, although some fraction of the mutants may be the ones
affected in membrane permeability. Similarly, RNAP mutants
may be obtained by growing bacteria on plates containing
rifampicin that targets RNAP. This feasibility has yielded
many successful examples of ribosome engineering, including
the enhanced production of secondary metabolites and
enzymes, as well as enhanced tolerance to toxic compounds
such as 4-hydroxybenzoate (Table 1). Ribosome engineering
was effective in enhancing the yield of secondary metabolites
in a wide range of structural classes, including polyketides,
macrolides, aminoglycosides, and nucleosides. Importantly,
the K88E and K88R mutations in rpsL (polypeptide amino
acid numbering according to Streptomyces coelicolor), which
encodes the ribosomal protein S12, and the H437Y and
H437R in rpoB, which encodes the RNAP β subunit, were
often effective (Table 1). In all these mutant strains of S.
coelicolor, overproduction of actinorhodin correlated with
higher expression of act II-ORF4, a pathway-specific positive
regulator of actinorhodin synthesis. Combinations of these
drug-resistance mutations further enhanced bacterial produc-
tivity (Tamehiro et al. 2003; Tanaka et al. 2009a). For exam-
ple, the introduction of eight different mutations enhanced
actinorhodin production by S. coelicolor 280-fold (Wang et
al. 2008) and the introduction of three mutations enhanced the
production of the enzyme cycloisomaltooligosaccharide glu-
canotransferase by Paenibacillus agaridevorans 1,000-fold
(Tanaka and Ochi, manuscript in preparation). Mutations in
rpsL enhanced expression of the frr gene, which encodes
ribosome recycling factor (Hosaka et al. 2006), and overex-
pression of frr in Streptomyces avermitilis increased avermec-
tin production, even in an industrial strain (Li et al. 2010).
Overexpression of frr may be a general method of boosting
translation during the stationary phase, leading to reinforce-
ment of secondary metabolism. The rif mutation S444F in-
creased erythromycin production by Saccharopolyspora
erythraea fourfold and metabolic changes induced by this
mutation were analyzed in detail using DNA microarrays
(Carata et al. 2009).
Construction of an amenable host organism for heterolo-
gous gene expression is a current goal for enhancing
yield and activating cryptic gene clusters (Baltz 2010;
Komatsu et al. 2010). Introduction of the rpsLK88Rmutation
into Streptomyces fradiae resulted in the efficient heterolo-
gous expression of secondary metabolite genes (Alexander et
al. 2010). Moreover, introduction of the rpsL K88E and rpoB
S433L mutations into S. coelicolor enhanced the production
of chloramphenicol and congocidine 40- and 30-fold, respec-
tively (Gomez-Escribano and Bibb 2011), and mutations con-
ferring resistance to lincomycin and kanamycin enhanced
violacein production in Escherichia coli 41-fold (Ahmetagic
and Pemberton 2011). Although the present review does not
focus on the host organism system for heterologous expres-
sion of secondary metabolite gene clusters, the most updated
review can be seen elsewhere (Komatsu et al. 2013).
The rsmG gene encodes a 16S rRNA methyltransferase,
which methylates position G527 of the 530 loop of 16S
rRNA (Okamoto et al. 2007). Mutations of this gene in
Streptomyces strains confer low-level resistance to strepto-
mycin and cause preferential overexpression of the metK
gene (at least in S. coelicolor), which encodes the enzyme S-
adenosylmethionine (SAM) synthetase, eventually leading
to an increase in intracellular SAM level (Nishimura et al.
2007). This increase, together with enhanced protein syn-
thesis during the late growth phase, results in overproduc-
tion of antibiotic (Kim et al. 2003; Okamoto et al. 2003).
Addition of SAM to the medium or propagation of metK
with multicopy plasmids also results in antibiotic overpro-
duction by various Streptomyces spp. and other actinomy-
cetes (Huh et al. 2004; Maharjan et al. 2008, 2012; Oh et al.
2010; Paudel et al. 2011; Saito et al. 2003; Shin et al. 2007;
Sun et al. 2012; Wang et al. 2007; Zhao et al. 2006, 2010).
Spontaneous rsmG mutations arise at a high frequency
(10−4–10−6) (Nishimura et al. 2007; Okamoto et al. 2007).
rsmG mutation (and also ksgA mutation [Ochi et al. 2009])
harbors several mysterious features (Nodwell 2007) and is
effective for not only enhanced antibiotic production but also
activation of cryptic secondary metabolite biosynthetic genes
(Tanaka et al. 2009b). When constructing strains combining
low-level (rsmG) and high-level (rpsL) streptomycin resistance
mutations, the mutations should be introduced in that order
(Tanaka et al. 2009a).
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Table 1 Improvement of antibiotic/enzyme production and cell’s physiology by subjecting to ribosome engineering
Strain Antibiotic/enzyme Mutation Comment Reference
Actinomycetes
S. coelicolor Actinorhodin rpsL(K88E or K88R) Using relC mutant Ochi et al. (1997)
S. coelicolor Actinorhodin rpsL(K88E) Streptomycin resistance Hesketh and Ochi (1997)
S. coelicolor Actinorhodin rpsL(P91S) Paromomycin resistance Okamoto-Hosoya et al. (2000)
S. coelicolor Actinorhodin rpsL(K88E) gen
rpoB(H437Y)
Triple mutation Hu and Ochi (2001)
S. coelicolor Actinorhodin rpoB(R440H or Q424L) Using relA and
relC mutants
Xu et al. (2002)
S. coelicolor Actinorhodin rpsL(K88E) Streptomycin resistance Hosaka et al. (2006)
S. coelicolor Actinorhodin rsmG Function-loss mutation Nishimura et al. (2007)
S. coelicolor Actinorhodin rpsL gen rpoB par
gnt fus tsp lin
Octuple mutation Wang et al. (2008)
S. coelicolor Actinorhodin rsmG Function-loss mutation Tanaka et al. (2009a)
S. coelicolor Actinorhodin rsmG rspL(R86P or K88E) Double mutation Tanaka et al. (2009a)
S. coelicolor Actinorhodin rpsL(K88E) Streptomycin resistance Tanaka et al. (2009a)
S. coelicolor Actinorhodin rpsL(K88E GI92) Double mutation with
paromomycin resistance
Wang et al. (2009a)




S. coelicolor Actinorhodin ery Erythromycin resistance Imai et al. (2012)
S. lividans Actinorhodin rpsL(K88E) S. lividans TK24 with str Shima et al. (1996)
S. lividans Actinorhodin rpoB(S433L or S433P) Rifampicin resistance Hu et al. (2002)
S. lividans Actinorhodin rpoB(R440C) Using relC mutant Lai et al. (2002)
S. lividans Actinorhodin rpsL(L90K or R94G) Site-directed mutagenesis Okamoto-Hosoya et al. (2003)
S. lividans Actinorhodin rsmG Function-loss mutation Nishimura et al. (2007)
S. lividans Actinorhodin cap Capreomycin resistance Zhang et al. (2008)





Tala et al. (2009)
S. lividans Actinorhodin ery Erythromycin resistance Imai et al. (2012)
S. antibioticus Actinomycin str Streptomycin resistance Hosoya et al. (1998)
S. antibioticus Actinomycin rsmG Function-loss mutation Tanaka et al. (2009a)
S. antibioticus Actinomycin rpsL(K88E) Streptomycin resistance Tanaka et al. (2009a)
S. antibioticus Actinomycin rsmG rspL(K88E or K88R) Double mutation Tanaka et al. (2009a)
S. parvulus Actinomycin rpsL(K88R) Streptomycin resistance Tanaka et al. (2009a)
S. parvulus Actinomycin rsmG Function-loss mutation Tanaka et al. (2009a)
S. parvulus Actinomycin ery Erythromycin resistance Imai et al. (2012)
S. griseus Streptomycin rsmG Function-loss mutation Tanaka et al. (2009b)
S. griseus Streptomycin ery Erythromycin resistance Imai et al. (2012)
S. erythraea Erythromycin rpsL(K43N) Streptomycin resistance Tanaka et al. (2009a)
S. erythraea Erythromycin rpoB(S444F) Rifampicin resistance Carata et al. (2009)
S. albus Salinomycin rpsL(K88R) gen rif Triple mutation in an
industrial strain
Tamehiro et al. (2003)
S. avermitilis Oligomycin rpsL(K43M or K88E) Streptomycin resistance Tanaka et al. (2009a)
S. bingchenggensis Milbemycin str Streptomycin resistance Wang et al. (2009b)
S. chattanoogensis Fredericamycin str Streptomycin resistance Hosoya et al. (1998)
S. fradiae A54145 rpsL(K88R) Streptomycin resistance Alexander et al. (2010)
S. incarnatus Sinefungin rpoB(D447G) Rifampicin resistance Fukuda et al. (2010)
S. lavendulae Formycin str Streptomycin resistance Hosoya et al. (1998)
S. mauvecolor Piperidamycin rpoB(H437L), gen,
or rpoB rpsL(K88R)
Single or double mutation Hosaka et al. (2009)
S. roseosporus A21978C rpsL(K43N) Streptomycin resistance Wang et al. (2012)
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Impact on silent gene activation
Promising approaches for the activation of cryptic bio-
synthetic gene clusters in Streptomyces species include
ribosome engineering; the addition of N-acetylglucos-
amine to the medium or deletion of the dasR gene,
which encodes anN-acetylglucosamine-responsive regulatory
protein, the constitutive overexpression of a pathway-specific
large ATP-binding LuxR-type (LAL) regulatory gene, meta-
bolic remodeling, and cell-to-cell interaction. These new
approaches may enable the identification of novel and/or
poorly understood antibiotics, such as piperidamycin and
stambomycin, and are all characterized by applicability to a
wide range of actinomycetes and potential scalability to high
throughput.
Ribosome engineering
Ribosome engineering is effective for activation of silent
genes. For example, among the 1,068 actinomycetes isolat-
ed from soil, a fraction of the Streptomyces isolates and most
of the non-Streptomyces isolates were found to be nonpro-
ducers of antibiotics, with 43 and 6 %, respectively, of these
nonproducing strains acquiring the ability to synthesize
antibacterials against Staphylococcus aureus after a selec-
tion step that generated spontaneous rpsL or rpoB mutations
(Hosaka et al. 2009). Assessment of Streptomyces mauve-
color 631689, a strain that produced no antibacterial activity
in any medium tested, demonstrated that two rpoB mutants
(H437D or H437L), a double mutant of rpoB (H437L) and
rpsL (K88R), and a gentamicin-resistant (GenR) mutant
Table 1 (continued)
Strain Antibiotic/enzyme Mutation Comment Reference
S. viridochromogenes Xylanase rpsL(K88R) Streptomycin resistance Liu et al. (2012)
A. orientalis Norvancomycin str rif Double mutation Wang et al. (2006)
P. rosea GE2270 str gen rif Triple mutation in an
industrial strain
Beltrametti et al. (2006)
Nonomuraea sp. Glycopeptide A40926 rpoB(H426N,
S431N, F445M,
S474Y, M581D)
"Natural" mutant-type rpoB Vigliotta et al. (2005)
Streptomyces sp. Antibiotics str Streptomycin resistance Hai et al. (2011)
Actinomycete Antitumor activity str Streptomycin resistance Han et al. (2009)
Actinomycete Antitumor activity str Streptomycin resistance Sun et al. (2010)
Actinomycete Antitumor activity str Streptomycin resistance Han et al. (2010)
Eubacteria
E. coli Cell-free protein synthesis rpsL(K87E) Streptomycin resistance Hosaka et al. (2004)
E. coli Cell-free protein synthesis rpsL(K42T) Streptomycin resistance Chumpolkulwong et al. (2004)
E. coli Replication progression rpoB(H447R) Rifampicin resistance Baharoglu et al. (2010)




B. subtilis Neotrehalosadiamine rpoB(S487L) Rifampicin resistance Inaoka et al. (2004)
B. subtilis α-Amylase rpsL(K56R) Streptomycin resistance Kurosawa et al. (2006)
B. subtilis Sporulation, germination,
competence
rpoB(H482R, H482Y) Rifampicin resistance Maughan et al. (2004)
B. subtilis Sporulation and tolerance rpoB Rifampicin resistance Moeller et al. (2012)
B. cereus FR900493 str Streptomycin resistance Hosoya et al. (1998)
C. acetobutylicum Aceton-Butanol str Streptomycin resistance Gao et al. (2012)
D. radiodurans Radiation resistance rpoB(L420R) Rifampicin resistance Hua et al. (2011)
P. luminescens Nematicidal activity rpoB(P564L) Rifampicin resistance Qiu et al. (2012)




Hosokawa et al. (2002)
P. pyrrocinia Pyrrolnitrin str Streptomycin resistance Hosoya et al. (1998)
Fungi
P. purprogenum Antitumor activity gen Gentamicin resistance Chai et al. (2012)
The genetic symbols, cap, ery, fus, gen, gnt, kan, lin, par, rif, str, and tsp indicate resistance to capreomycin, erythromycin, fusidic acid, gentamicin,
geneticin, kanamycin, lincomycin, paromomycin, rifampicin, streptomycin, and thiostrepton, respectively. rpsL and rpoB indicate the genes coding
for the ribosomal protein S12 and the RNA polymerase β-subunit, respectively
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produced a family of antibiotics, the piperidamycins (Fig. 1).
The activation of silent genes by the rpoB H437D or H437L
mutations was attributed, at least in part, to the increased
affinity of mutant RNAP for the silent gene promoters
(Hosaka et al. 2009).
Species of Bacillus produce a variety of commercially
important metabolites and extracellular enzymes. The intro-
duction of the rpoB mutation S487L into a Bacillus subtilis
strain resulted in cells that overproduced an aminosugar anti-
biotic, 3,3′-neotrehalosadiamine (NTD), the production of
which is dormant in the wild-type strain (Inaoka et al. 2004).
Perhaps, unlike the wild-type RNAP, the mutant RNAP effi-
ciently recognized the σA-dependent promoters, resulting in
the dramatic activation of the NTD biosynthesis pathway.
Although most of the work was performed using S. lividans,
we have now demonstrated that rpoB mutations are widely
effective in activating silent and poorly expressed secondary
metabolite-biosynthetic gene clusters at the transcriptional lev-
el in Streptomyces griseus (up to 70-fold activation), S. coeli-
color (up to eightfold activation), and S. erythraea (up to
sevenfold activation; Tanaka and Ochi, manuscript in prepara-
tion). Notably, the activation of silent gene clusters by rpoB
mutations was medium-dependent, with each rpoB mutation
exerting differential effects on the activation of each silent gene
cluster. These findings suggest that strains containing rpoB
mutations (e.g., H437Y, H437R) should be grown in different
media to assess the full spectrum of silent gene activation.
The recent observation, that several actinomycetes possess
two rpoB genes (Vigliotta et al. 2005), has suggested a new
strategy of activating silent gene expression in bacteria. Two
rpoB paralogs, rpoB(S) and rpoB(R), provide Nonomuraea
sp. strain 39727 with two functionally distinct and develop-
mentally regulated RNAPs. The product of rpoB(R), the ex-
pression of which increases after transition to stationary phase,
is characterized by five amino acid substitutions (H426N,
S431N, F445M, S474Y, and M581D) located within or close
to the rifampicin resistance cluster. The expression of rpoB(R)
was found to markedly activate antibiotic biosynthesis, with
the rpoB(R)-specific H426N mutation found essential in acti-
vating secondary metabolism (Tala et al. 2009). Additional rif
cluster-associated rpoB(R)-specific missense mutations likely
interact functionally with the H426N mutation, leading to the
marked effect of rpoB(R). Mutant type, or duplicated, rpoB
often exists in nature, with rpoB gene polymorphisms detected
in five of 75 inherently rifampicin-resistant actinomycetes
isolated from nature, although these polymorphisms were
preferentially distributed in the so-called rare actinomycetes,
not in Streptomyces spp. Notably, all but one of these
rifampicin-resistant rare actinomycete isolates obtained to date
were able to produce antibiotics (Tala et al. 2009).
From a practical viewpoint, these findings suggest the
intriguing possibility of using rpoB(R)-based technology to
improve strains and to search for novel bioactive molecules by
activating silent genes. This technology should have greater
potential than the simple rif selection currently used to im-
prove the production of secondary metabolites, as the intro-
duction of rpoB(R) enhanced antibiotic production eightfold
when compared with the introduction of the H426Y mutation
(Tala et al. 2009). It is also of interest to examine whether
various rpoB(R) forms found in nature are more capable of
activating silent bacterial genes than Nonomuraea rpoB(R).
Thus, understanding the status of natural rpoB(R) and utilizing
it for cryptic gene activation may provide new horizons for
medical and industrial microbiology.
dasR–N-acetylglucosamine system
DasR is a global regulator of antibiotic biosynthesis, which
links nutrient stress to antibiotic production by Streptomyces
(van Wezel and McDowall 2011). N-acetylglucosamine
(GlcNAc), a major component of the cell walls of fungi, is
the second most abundant polysaccharide in nature. A high
concentration of GlcNAc, perhaps mimicking its accumula-
tion after autolytic degradation of the vegetative mycelium,
may be a major checkpoint for the onset of secondary metab-
olism (Rigali et al. 2008). The response is transmitted to
antibiotic pathway-specific activators through the pleiotropic
transcriptional repressor DasR, suggesting a new strategy for
activating pathways of secondary metabolite biosynthesis. In
S. coelicolor, GlcNAc (∼10 mM) blocks development and
antibiotic production under rich growth conditions, but trig-
gers antibiotic production and sporulation under poor nutri-
tional conditions (i.e., minimal medium), suggesting that the
effect of GlcNAc depends on the specific culture conditions.
GlcNAc also stimulated antibiotic production by other











































































Fig. 1 Detection of antibacterial
compounds produced by drug-
resistant mutants of S. mauve-
color 631689. a HPLC profiles
of culture extracts. The arrows
(A–H) indicate the bioactive
fractions. b The chemical struc-
tures of the antibacterial com-
pounds isolated
Appl Microbiol Biotechnol (2013) 97:87–98 91
Streptomyces collonus, S. griseus, Streptomyces hygroscopi-
cus, and Streptomyces venezuelae (Rigali et al. 2008).
The GlcNAc regulon is controlled by the GntR regulator
DasR, the DNA-binding activity of which is inhibited by
glucosamine-6-phosphate. Introduction of mutations into
dasR effectively enhanced antibiotic productivity. For example,
the S. coelicolor dasRmutant BAP29 showed three- to fourfold
enhanced and accelerated production of pigmented antibiotics
(Rigali et al. 2008). The position of the DasR binding site in the
act II-ORF4 promoter indicates that DasR represses transcrip-
tion of this gene. Interestingly, the dasR mutant BAP29 was
found to be awakened for cryptic gene clusters encoding a
hypothetical antibiotic made by a type I modular polyketide
synthase (SCO6273-6288), showing that this method is appli-
cable for activating silent gene clusters (Rigali et al. 2008).
LAL regulatory system
Constitutive overexpression of a putative pathway-specific
LAL regulator was shown to successfully induce the expres-
sion of the silent type I modular polyketide synthase (PKS)
gene cluster in Streptomyces ambofaciens 23877, enabling the
identification of a unique structural class of polyketides with
promising antitumor activity (Laureti et al. 2011). S. ambofa-
ciens 23877 produces two antibiotics, the macrolide spiramy-
cin and the pyrrole-amide congocidine. Sequence analysis of
its genome showed that S. ambofaciens 23877 contains sev-
eral secondary metabolite biosynthetic gene clusters, includ-
ing a giant type I modular PKS gene cluster. This cluster is
composed of 25 genes, nine of which encode PKSs, and
spans almost 150 kb, making it one of the largest polyketide
biosynthetic gene clusters described to date. The metabolic
product(s) of this gene cluster have not been determined and
transcriptional analyses showed that this cluster is not
expressed under laboratory growth conditions. The constitu-
tive expression of a regulatory gene within this cluster, encod-
ing a protein that is similar to the LAL family of proteins,
triggered the expression of the biosynthetic genes. This led to
the identification of four 51-membered glycosylated macro-
lides, named stambomycins A–D, as metabolic products of
the gene cluster (Laureti et al. 2011). Database searches have
identified genes that encode LAL regulators within numerous
cryptic biosynthetic gene clusters in actinomycete genomes,
for which metabolic product(s) remain to be discovered, sug-
gesting that constitutive expression of such pathway-specific
activators represents a powerful approach for the discovery of
novel bioactive natural products.
The metabolism-remodeling approach
Although activation of biosynthetic genes at the transcrip-
tional level is primarily important for exploiting useful
metabolites, perturbation of biosynthesis by modulating,
for example, the supply of precursors may also be a promis-
ing approach to enhancing the cell’s capability to produce
secondary metabolites, a process termed metabolic engineer-
ing (Olano et al. 2008). One method of enhancing the yields of
secondary metabolites consists of modulating fatty acid bio-
synthesis using small molecules. For example, screening of a
large number (>30,000) of small molecules, seeking candi-
dates that might “remodel” the yields of actinorhodin in S.
coelicolor, identified 19 compounds that caused elevated or
precocious production of actinorhodin (Craney et al. 2012).
Further examination of four of these 19 molecules, antibiotic
remodeling compounds (ARC)2, 3, 4, and 5, showed that (1)
low concentrations of ARC2 enhanced the yield of actino-
rhodin, (2) the ARC2 effect can be observed in other actino-
mycetes, suggesting that the molecular target and mechanism
of ARC2 is conserved in various actinomycetes, and (3)
several of the most active molecules are structurally similar
to the known antimicrobial agent triclosan, an inhibitor of
fatty acid synthesis. The ARC2 effects therefore involve the
inhibition of the enoyl reductase activity of FabI, an enzyme
that catalyzes the final and rate-limiting step in fatty acid
biosynthesis. Since fatty acid and polyketide synthesis share
the precursors acetyl-CoA and malonyl-CoA, partial inhibi-
tion of fatty acid synthesis could recruit those acyl-CoAs
preferentially to polyketide biosynthesis.
The ARC2 series of molecules not only enhanced the
yields of known antibiotics, but induced the production of as
yet unidentified compounds in Streptomyces peuceticus, com-
pounds that could not be detected in the absence of ARC2
(Craney et al. 2012). Conceivably, the expression levels of the
genes encoding the enzymes to synthesize these compounds
are very low (i.e., nearly but not entirely silent), so that
reinforcement of the biosynthetic process by an efficient sup-
ply of substrate made possible their detection. Alternatively,
some other yet-unknown mechanism may be involved in the
observed phenomenon. Theoretically, this approach may be
enhanced by combination with the transcription-associated
approaches (Ochi and Okamoto 2012). It may be possible to
develop similar approaches for other classes of antibiotics,
such as aminoglycosides and nonribosomal peptides, to access
the full spectrum of secondary metabolites.
Approach from cell-to-cell interactions
Co-culture is an effective method of inducing the production
of cryptic metabolites. Although some co-culture methods
have been reported, these methods are often specific to two
bacterial strains. This limitation may be overcome by a
novel fermentation method, the combined culture method,
involving the co-culture of two bacterial strains (Onaka et al.
2011). Mycolic acid-containing bacteria could influence the
biosynthesis of cryptic natural products in Streptomyces spp.
The production of red pigment by S. lividans was induced
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by co-culture with Tsukamurella pulmonis, a mycolic acid-
containing bacterium. Importantly, co-culture with T. pulmo-
nis improved or inhibited natural product biosynthesis in 88%
of the Streptomyces strains isolated from soil: the production
of new secondary metabolites was detected in 37 % of strains,
while increased metabolite production was detected in
55 % of strains. The other mycolic acid-containing bacteria,
Rhodococcus erythropolis and Corynebacterium glutamicum,
improved or inhibited biosynthesis in 87 and 90 % of the
Streptomyces strains, respectively: the production of new sec-
ondary metabolites was detected in 32 and 24 % of strains,
respectively. Co-culture of T. pulmonis with Streptomyces
endus led to the identification of a novel antibiotic, alchive-
mycin A. The addition of mycolic acid into the medium of
pure S. lividans cultures had no effect on antibiotic produc-
tion, suggesting that mycolic acid localized to the outer cell
layer of the inducer bacterium affected secondary metabolism
in Streptomyces, with this activity resulting from the direct
cell-to-cell interaction of the two bacterial strains (Onaka et al.
2011). This method is also scalable for inducing the produc-
tion of cryptic antibiotics, as it only involves the addition of a
mycolic acid-containing bacterium to a pure culture of an
actinomycete.
Applicability of ribosome engineering to myxobacteria
Interest in myxobacteria, an important source of novel clas-
ses of secondary metabolites, has increased. The genomes of
myxobacteria are large (9.14 Mb in Myxococcus xanthus
and 13.03 Mb in Sorangium cellulosum), similar or larger
than the genome of S. coelicolor (8.67 Mb). Myxobacterial
genomes have been found to encode many genes involved
in the synthesis of secondary metabolites (e.g., 8.6 % of the
M. xanthus genome), opening the possibility of discovering
clinically relevant natural products (Goldman et al. 2006;
Schneiker et al. 2007; Wenzel and Muller 2009). Of the
myxobacteria, the genus Sorangium is particularly valuable,
as 46 % of metabolites isolated from myxobacteria are
derived from this genus. Most myxobacterial metabolites
are polyketides, nonribosomal peptides, and hybrids of the
two structures. Hence, activation or enhancement of cryptic
genes in the genus Sorangium is of interest, and the strategy
of ribosome engineering may be utilized successfully for
drug discovery.
Applicability of ribosome engineering to eukaryotes
Fungi have been among the most important sources of bio-
logically active secondary metabolites. Following the publi-
cation of the complete genome sequence of the model yeast
Saccharomyces cerevisiae (Goffeau et al. 1996), hundreds of
fungal genome projects have been carried out worldwide. As a
result, large numbers of fungal genome sequences are now
available publicly, including those of well-known producers
of secondary metabolites, such as Aspergillus oryzae and
Penicillium chrysogenum (Ma and Fedorova 2010). Their
genomes, like those of Streptomyces, are also enriched in
genes involved in secondary metabolite biosynthesis. Similar
to Streptomyces, however, most biosynthetic gene clusters in
fungi are either silent or expressed at very low levels under
laboratory conditions. Thus, understanding the physiological
conditions under which these genes are activated and devel-
oping a pragmatic approach for utilizing such genetic potential
is important. A simple and yet efficient approach to isolate
more secondary metabolites by exploring the genetic potential
in fungi is to vary easily accessible cultivation parameters
(Bode et al. 2002). Alternatively, physiological interaction
among microorganisms may be practical. For example, co-
cultivation of Aspergillus nidulans and Streptomyces rapamy-
cinicus selectively stimulated cryptic fungal gene clusters
involved in the biosynthesis of secondary metabolites, such
as orsellinic acid, lecanoric acid, and the cathepsin K inhib-
itors F-9775A and F-9775B (Schroeckh et al. 2009). Small
molecule epigenetic modifiers, such as the DNA methyltrans-
ferase inhibitor 5-azacytidine and the histone deacetylase in-
hibitor suberoylanilide hydroxamic acid, have been shown
effective not only in altering secondary metabolite profiles
but in generating new biomolecules (Williams et al. 2008).
Likewise, nucleoid structure may be playing an analogous
role to fungal chromatin structure in controlling transcriptional
programs in actinomycetes, thus Moore et al. (2012) reported
chemical elicitors that stimulate biosynthetic gene clusters in
Streptomyces.
The concept based on bacterial ribosome engineering, as
described above, has been applied to fungi to produce
secondary metabolites. For example, introduction of genta-
micin resistance into the marine-derived fungal strain
Penicillium purpurogenum G59 effectively activated silent
gene clusters for secondary metabolites (Chai et al. 2012).
Although gentamicin did not inhibit this strain G59 during
routine testing, treatment of G59 spores with high concen-
trations of gentamicin, in combination with dimethyl sulf-
oxide, inhibited strain growth, allowing the development of
gentamicin-resistant colonies on agar plate. This method
produced four antitumor secondary metabolites not found
in the secondary metabolites of other P. purpurogenum
strains. In addition, hygromycin B-resistant mutants of
Monascus pilosus NBRC 4520 that exhibited enhanced
production of secondary metabolites could be isolated using
the general method used to obtain drug-resistant mutants in
bacteria (Hosaka and Mizukami, unpublished data), because
hygromycin B is an aminoglycoside antibiotic that potently
inhibits protein synthesis in both prokaryotic and eukaryotic
cells (Gonzalez et al. 1978). These findings indicate that
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modulation of ribosomal function may be applicable to a
variety of fungi to elicit their potential secondary
metabolism.
A new insight into the silent gene activation in the eukary-
otic microorganisms is also coming from the ectopic ppGpp
expression. The bacterial alarmone ppGpp, produced by
RelA-SpoT homologue (RelA or RSH) on the ribosome in
response to nutrient limitation, is a key signal factor to initiate
the onset of bacterial secondary metabolism (Bibb 2005; Ochi
2007). Although relA and RSH, the genes encoding ppGpp
synthetase, are distributed widely in bacteria and plants
(Givens et al. 2004; Takahashi et al. 2004; Tozawa and
Nomura 2011; van der Biezen et al. 2000), neither of these
genes, nor ppGpp itself, has yet been identified in animals or
eukaryotic microorganisms. Despite the essential lack of a
relA-spoT homologue and ppGpp in the yeast S. cerevisiae,
its heterologous expression of a relA-spoT homologue (Sj-
RSH) isolated from the halophilic plant Suaeda japonica
resulted in the accumulation of ppGpp, accompanied by the
enhancement of tolerance against various stressors, including
osmotic stress, ethanol, and freezing (Ochi et al. 2012;
Yamada et al. 2003). Low levels of ppGpp [10–20 pmol (mg
dry weight)−1] were sufficient for cellular stress tolerance
without affecting growth rate (Ochi et al. 2012). These results
raise an intriguing possibility that the ppGpp system can be
applicable to the silent gene activation in such eukaryotic
microorganisms as fungi.
Applicability of rare earth elements to biotechnology
Despite the importance of rare earth elements (REEs) in the
chemical industry, little is known about their biological effects
in living cells. These elements, however, have recently been
shown involved in the overproduction of antibiotics and in the
activation of silent or poorly expressed genes in bacteria. The
REEs consist of 17 elements, including scandium, yttrium,
and the lanthanides (i.e., the 15 elements from lanthanum (La)
to lutetium in the periodic table). Low concentrations (10–
100 μM) of scandium (Sc) added to cultures of S. coelicolor
(an actinorhodin producer), Streptomyces antibioticus (an ac-
tinomycin producer), and S. griseus (a streptomycin producer)
were found to enhance antibiotic production 2–25-fold
(Kawai et al. 2007). The effects of Sc were exerted at the level
of transcription of pathway-specific positive regulatory genes,
as demonstrated by marked upregulation of act II-ORF4 in S.
coelicolor. Notably, REEs were effective in activating silent
and poorly expressed secondary metabolite biosynthetic genes
in Streptomyces. That is, the addition to the medium of low
concentrations of Sc or La activated the expression of nine
genes, 2.5 - to 12-fold, belonging to nine secondary metabo-
lite–biosynthetic gene clusters of S. coelicolor (Tanaka et al.
2010). HPLC analysis of ethyl acetate-extractable metabolites
indicated that several compounds could be detected only in
the REE-treated cultures. This approach, due to its feasibility,
should facilitate the discovery of new biologically active
compounds. The ability of REEs (especially Sc) to enhance
enzyme production and secondary metabolism was also ob-
served in B. subtilis. The addition of Sc to the growth medium
stimulated the production of both α-amylase and bacilysin at
the transcriptional level (Inaoka and Ochi 2011).
REEs have long been known to have weak antimicrobial
potency. Thus, it was possible to develop Sc-resistant mutants
on plates containing Sc. As expected, actinorhodin overpro-
ducers (Ochi, unpublished results) and α-amylase overpro-
ducers (Inaoka and Ochi 2012) were often found among the
mutants of S. coelicolor and B. subtilis, respectively. In B.
subtilis, a mutation in the uppS gene, which encodes the
enzyme undecaprenyl pyrophosphate synthase, was responsi-
ble for the Sc resistance phenotype and α-amylase overpro-
duction. This uppS86 mutation, however, did not affect the
levels of amyE expression, suggesting that this mutation
exerted its effects at the post-transcriptional level (Inaoka
and Ochi 2012). Thus, the mechanism by which α-amylase
production was stimulated by the uppS86 mutation differed
from that caused by the addition of Sc to the growth medium.
An important advantage of using REEs is that this method
does not require any gene engineering technology or genomic
information on the strains examined. Since REEs are distrib-
uted ubiquitously throughout the world, it is conceivable that
microorganisms have acquired the ability to respond to low
levels of these elements over the course of their long evolu-
tionary history, possibly as a means of adapting their physiol-
ogy to prevailing conditions. The effect of low concentrations
of Sc on antibiotic production indicates that Sc functions in
situ as a factor that induces or stimulates the production of
secondary metabolites, including pigments, mycotoxins, phy-
totoxins, and antibiotics. “Rare earth microbiology” may thus
offer new insight into entirely unknown regulatory events that
occur in all organisms.
Concluding remarks
The availability of genome sequence information on various
microorganisms and newly developed methods of activating
silent and poorly expressed genes suggest that natural product
research has now entered a promising new era. Particular
attention should be paid to combined approaches that include
the transcription activation of key genes and metabolism
remodeling. Reinforcement of biosynthetic processes by effi-
cient substrate supply may be synergistic with transcription
activation, eventually leading to the efficient discovery of new
secondary metabolites. Another point of interest is the appli-
cation of ribosome engineering to activate the silent biosyn-
thetic pathways in fungi and myxobacteria, which may result
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in the efficient exploitation of novel secondary metabolites of
these microbial groups. Also, since ppGpp enhances yeast cell
tolerance to various stress stimuli, the ability of ectopic ppGpp
in fungal cells to induce the synthesis of novel secondary
metabolites is of interest. Apart from the technology, it would
be important to envisage the reason why cryptic genes are
silent in the laboratory fermentation conditions. Are the silent
genes expressed under the special yet-unknown environmental
conditions? If so, do the cryptic secondary metabolites play an
intrinsic biological role(s) for producing organisms under the
special environmental conditions? What are such special envi-
ronmental conditions, if any? Understanding the mechanism(s)
underlying the silencing of cryptic genes would help to fully
untilize the microbial gene clusters for secondary metabolism.
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